
|Videos|October 18, 2021
Study finds UGN-102 well-tolerated in patients with NMIBC
Author(s)Urology Times staff
Advertisement
In this video, William C. Huang, MD, discusses the findings and takeaways of a recent phase 2b trial published in the Journal of Urology, which investigates the agent UGN-102 as a treatment for patients with non–muscle-invasive bladder cancer (NMIBC). Huang is a professor in the departments of urology and radiology at the New York University Grossman School of Medicine and the chief of urology at Tisch Hospital, New York City.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
FDA approves cefepime and zidebactam for complicated UTI
3
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
4
Enzalutamide associated with greater cognitive decline than darolutamide in advanced prostate cancer
5











